

Grape King Bio(1707 TT) Investor Presentation

September 2019

Confidential

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject
 to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those in the guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

Investment Highlights

ü We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements.

ü We operate the second largest direct-selling company – Pro-Partner in Taiwan (2016 market share: 9.8%).



Strong R&D capabilities

We are industry leader


- **ü** We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- ü Our expertise in raw materials allow us to develop health supplements serving different benefits. Therefore, many of our products are TFDA approved for different health benefits.
- **ü** We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ü We have delivered a solid earnings during 2008-2018 (CAGR of 23%/average ROE 21%).
- **ü** We have maintained more than 60% dividend payout in the past five years.
- **ü** On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.





Company Overview : Three core business units



Locus of all key ingredient design, formulation, and production for the whole Group.


2. Pro-Partner (60%-own) Taiwan direct selling distribution

A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.



3. Grape King Shanghai (100%-own) China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.





" **Competitive Strengths - Strong Products Capabilities** We acquired more than 52 patents and published over 20 research papers. Also, we acquired more than 10 TFDA Health Food certifications on our products. Brain Eye protection Yo-Shi Premium Lutein With TFDA Lion's Mane Health Food Mushroom Powder certifications Feminine beauty **Respiratory system** Snow Brightening Essential Drink Bai Ke Sz **Blood sugar** Immune system "Sugar Safe" Roseroot pills Ganoderma King × LING ZHI ANTIALLERGY × 995 Bio-tech Nourishment 🕤 Antrodia Bio Aid Liver protection Pro-Partner Meal Supplement Gastrointestinal health LGG PROBIOTICS PROBIOTICS Stomach KING PROBIOTICS & PREBIOTICS Wei-Jie PLUS < OLIGO PROBIOTICS < Probiotics & Prebiotics Super 13 **Probiotics & Prebiotics** Energy ComeBest Series . Golden Menopause symptoms ComeBest > PowerBOMB Fu Jia Ning



Competitive Strengths - State-of-the-Art Production Facilities




1. Grape King Taiwan

66



⁴⁴ Taiwan - Grape King Brand Sales Channels





Energy drinks that restore energy and provides necessary vitamins

Liver protection and hangover prevention and alleviation



Our third best seller – Probiotics King 9.7% of 2018 revenue

Improves digestion and defecation

Our fourth best seller Ganoderma King 9.2% of 2018 revenue

截过子宽健2

免疫調節做得好

日相目

北橋 11年

愛芝第一品牌

Strengthens the immune system and suppress allergic reactions

2. Pro-Partner



66

Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest local direct selling company in Taiwan based on revenue.
- One of the fastest growing direct selling companies in Taiwan (20% sales CAGR from 2008 to 2018)
- Second largest overall direct selling company in Taiwan. (2016 market share: 9.8%)
- Smallest product range 28 Health and Beauty products among the top 5
- No. 49 in the worldwide direct selling company rankings for 2018

(Source: 2019 DSN Global 100- based on 2018 revenues)







Our future star – Daily Light


Daily Light is our new product launched in 2018 which targets weight management and is popular among our female members.

How is Pro-Partner different from other direct selling companies?

< 19

Products purchase	Products' uniqueness	Support	Training	Compensation
 No minimum purchase requirement. No inventory pressure. (Members buy products directly from the company) 	 ü Higher entry barrier for Products (bio- researched and engineered). ü Symbol of national certifications. ü Products are mostly manufactured in- house rather than outsourced. 	ü Managed by Grape King, a well-respected health food company in Taiwan, so we can offer dedicated customer service and support.	 ü All the trainings and venues are held by the company, so we can have consistent training quality. ü All the trainings are free to members. 	 Ü Transparent compensation structure. Ü All purchases can be accumulated. Ü All compensation are paid to sales contribution and directly to the members by the company.

How is Pro-Partner different from other direct selling companies?



Healthy membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group.



3. Grape King Shanghai

66



" **Grape King Shanghai Overview**

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape ٠ King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.

Grape King Shanghai operating profit (Rmb m)

Product series


TE

Health

Beauty Energy

drink

€°





Long-term Goals

Our Group Goals

- Become a global leading herbal-and probiotics-based supplement supplier.
- Transform Grape King into a group enterprise.
- Grape King own brand, Pro-Partner, and Grape King Shanghai each to contribute 1/3 of consolidated revenue.

Med-term Goals

- Become a major herbal- and probiotics-based supplement supplier in Asia.
- Establish retail channels in China.
- China business to continue delivering double-digit growth.

Near-term Goals

- Continue to improve brand equity.
- Continue to invest in food safety measures and protection.
- Smooth ramp-up for our capacity expansion.
- Consolidated revenue to resume to double-digit growth.

Our Growth Stategies

 $\mathbf{n}\mathbf{2}$

03

Sustainable

double-digit

topline growth

Key Objectives

Grape King Taiwan

- Brand expansion
- Market share gain
- Accelerate overseas ODM & raw materials supply businesses

Pro-Partner

- Regain growth momentum
- Accurate time to market & improve demand forecast

Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom

Levers

- **ü** Brand expansion and new channels penetration (offline & online) under company's 50-Year anniversary marketing campaign.
- ü Continue to research and develop new products that are suitable for the market.
- **ü** Continue to participate in overseas exhibitions and competition to promote Grape King's raw material and R&D capabilities.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- ü Improve supply chain management to ensure no supply disruption.
- **ü** KPIs implementation for timely product launches and accuracy in demand forecast.
- ü Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- ü Continue to promote Grape King's product expertise in probiotics

Growing our online sales channel


















" **Financial Highlights**



Historical EPS vs. ROCE





Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.




expansion in Taiwan and Shanghai.

Historical cash dividend payout

Revenue Breakdown(2018 v.s. 2017)

2018 Revenue



1.Grape King Taiwan NT\$ 0.4 bn (+10% YoY)

Improved own brand sales in 2H18 owing to new products and our 50-year anniversary sales

2.Pro-Partner NT\$ 7.4 bn (+2% YoY)


Slower membership growth as the business continues to recover

3.Grape King Shanghai NT\$ 1.4 bn (+51% YoY)

Strong OEM/ODM demand from local directselling and Wechat customers



Revenue Breakdown(1H19 v.s. 1H18)



1.Grape King Taiwan NT\$ 247 m (+40% YoY)


Successful anniversary campaign of own brand products and increased shipments from our overseas ODM business

2.Pro-Partner NT\$ 3,700 m (+4% YoY)

Sales momentum further improved on the back of membership growth and new product launches


3.Grape King Shanghai NT\$ 510 m (-15% YoY)

100 days crack-down and further restrictions by the government impacted the overall direct/wechat selling industry.



Pro-Partner Grape King Shanghai Grape King Taiwan

Revenue Breakdown(2Q19 v.s. 2Q18)



Notes: Net profit breakdown is based on our annual report.

1.Grape King Taiwan NT\$ 148 M (+55% YoY)

Successful anniversary campaign of own brand products and increased shipments from our overseas ODM business


2.Pro-Partner

NT\$ 2,000 m (+2% YoY)

Mainly due to transition of our probiotics products, as we ended the sales of the old one in June. The new product is available since July.

3.Grape King Shanghai NT\$ 278 m (-18% YoY)

The crack down on illegal practices in direct selling/wechat selling has further intensified in 2Q19, which caused our ODM customers to hold back orders placing/shipment



⁶⁶ Five-Year Income Statement

(NT\$ m)	2014	2015	2016	2017	2018	1H19	YoY (%)						
							2014	2015	2016	2017	2018	1H19	
Revenue	6,283	7,248	9,185	9,388	9,183	4,414	11.4	15.4	26.7	2.2	(2.2)	2.8	
Gross Profit	5,561	6,385	7,919	7,865	7,329	3,582	11.6	14.8	24.0	(0.7)	(6.8)	4.0	
Operating Expenses	(3,961)	(4,573)	(5,685)	(5,610)	(4,979)	(2,554)	8.4	15.4	24.3	(1.3)	(11.2)	4.9	
Operating Profit	1,600	1,812	2,234	2,254	2,350	1,027	20.3	13.3	23.3	0.9	4.2	1.7	
Non Operating Income/(Loss)	89	70	78	151	77	45	(8.1)	(21.5)	11.8	92.6	(49.2)	27.3	
Pretax Income	1,689	1,883	2,312	2,405	2,427	1,073	18.4	11.4	22.8	4.0	0.9	2.6	
Tax Expenses	(303)	(336)	(426)	(471)	(537)	(226)	23.1	10.9	26.8	10.6	14.0	(7.2)	
Minority interest	(444)	(495)	(590)	(583)	(595)	(269)	28.4	11.5	19.2	(1.3)	2.1	6.9	
Net Income to Parent	942	1,052	1,297	1,352	1,295	577	12.8	11.6	23.3	4.3	(4.2)	4.9	
Basic EPS (NT\$)	7.24	8.07	9.82	10.03	9.57	4.25	12.8	11.5	21.7	2.1	(4.6)	4.4	
Key Financial Ratios (%)													
Gross Margin	88.5	88.1	86.2	83.8	79.8	81.1							
Operating Expense Ratio	63.1	63.1	61.9	59.8	54.2	57.9							
Operating Margin	25.5	25.0	24.3	24.0	25.6	23.3							
Effect Tax Rate	17.9	17.8	18.4	19.6	22.1	21.1							
Net Margin	15.0	14.5	14.1	14.4	14.1	13.1							

37

⁶⁶ Five-Year Balance Sheet

(NT\$ m)	2014	2015	2016	2017	2018	1H19	YoY (%)					
	2014						2014	2015	2016	2017	2018	1H19
Total Assets	5,369	8,612	9,550	9,892	10,648	10,530	16.0	60.4	10.9	3.6	7.6	4.2
Cash	1,374	1,433	1,899	1,920	2,050	1,251	28.6	4.3	32.6	1.1	6.8	2.4
AR & NR	98	97	204	160	171	273	14.0	(1.9)	111.6	(21.5)	6.8	4.6
Inventories	268	359	435	492	563	546	14.1	34.0	21.0	13.1	14.4	4.9
Fixed Assets	2,068	5,597	6,084	6,355	5,927	6,467	13.6	170.6	8.7	4.5	(6.7)	1.1
Total Liabilities	1,652	4,393	3,767	3,564	3,715	4,162	17.3	165.9	(14.3)	(5.4)	4.2	(3.7)
AP & NP	128	153	198	323	262	242	45.9	19.2	29.6	63.2	(18.9)	(13.9)
Total Borrowing	0	2,439	1,206	1,022	1,119	606	-	-	(50.6)	(1 5. 2)	9.5	(25.6)
Total Equity	3,717	4,220	5,783	6,328	6,933	6,368	15.4	13.5	37.1	9.4	9.6	10.1
Key Financial Ratios (%)												
A/R Turnover Days	5.3	4.8	5.9	7.0	6.5	10.9						
Inventory Turnover Days	125.6	131.0	113.0	109.5	102.4	115.3						
A/P Turnover Days	53.9	58.6	49.9	61.6	56.8	56.6						
Cash Conversion Days	77.0	77.2	69.0	54.9	52.1	69.7						
ROE (%)	32.3	32.1	31.3	27.0	23.7	22.3						
ROA (%)	18.9	15.0	14.3	13.9	12.6	11.2						
Net debt (cash)/Equity %	(37.0)	23.9	(12.0)	(14.2)	(13.4)	(10.1)						

38

Dividend Payout and Capex

(NT\$ m)	2012	2013	2014	2015	2016	2017	2018
Net profit	619	836	942	1,052	1,297	1,352	1,295
Cash dividend	482	651	690	730	862	903	883
DPS (NT\$)	3.7	5.0	5.3	5.59	6.4	6.68	6.5
Payout ratio	77.9%	77.9%	73.2%	69.4%	66.5%	66.8%	67.9%
Cash yield	3.1%	3.4%	2.4%	2.6%	3.2%	2.9%	3.1%
Сарех	159	355	187	2,635	736	772	1,116

Notes:

1. Cash yield is calculated based on Grape King's closing share price on June 12, 2019

2. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.

3. The estimated capex for 2019 will be used for 1) Grape King Bio-Tech Research Institute, and 2) various upgrade and new production lines projects.






Appendix: Industry Trends

Confidential

Taiwan health food industry

Taiwan's health food industry is growing


Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.



We keep gaining market share in Taiwan

We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.


Grape King's market share in Taiwan health food industry



Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system


- 1) Dessenable preduct price (merly up on p
- 1) Reasonable product price (mark-up on pricing);
- 2) Reasonable compensation structure (distribution of profit)

Member's system

According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration Pro-Partner has highest sales per product among top 3 players



ompany data. FTC. Taiwan Association of Direct Sel

China health food industry




Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.

China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



Grape King is the 7th largest distributor globally


We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.



China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020


China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.



China Probiotics Market (2014-2020)

Taiwan and China probiotic supplement market are expected

According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.



Probiotics Supplements Retail Value (2016-2021)

